Table 1. Study Characteristics.
| Characteristic | Mean (SD) | |||
|---|---|---|---|---|
| AREDS | FAM/DSGA | GATE | Combined | |
| Samples, No. | 349 | 164 | 422 | 935 |
| Baseline square root geographic atrophy area, mm | 2.31 (1.42) | 2.14 (1.09) | 2.60 (0.84) | 2.41 (1.14) |
| Square root–transformed geographic atrophy growth rate, mm/y | 0.294 (0.278) | 0.298 (0.175) | 0.296 (0.16) | 0.295 (0.214) |
| Age at blood sampling, y | 70.0 (5.3) | 75.9 (7.1) | 78.1 (7.7) | 74.7 (7.8) |
| Female, No. (%) | 195 (55.9) | 106 (64.6) | 246 (58.3) | 547 (58.5) |
| Follow-up time within study, y | 5.6 (3.2) | 3.3 (2.4) | 1.9 (0.5) | 3.6 (2.8) |
| Geographic atrophy lesions, No. | 1.7 (1.1) | 2.7 (2.3) | 3.6 (2.3) | 2.7 (2.1) |
| Participants with a single geographic atrophy lesion, No. (%) | 151 (43.3) | 51 (31.1) | 35 (8.3) | 237 (25.4) |
| Age-related macular degeneration genetic risk scorea | 41.36 (5.19) | 41.76 (5.32) | 41.47 (5.03) | 41.48 (5.14) |
| Individuals with geographic atrophy in both eyes, No. (%) | 206 (59.0) | 95 (57.9) | 291 (69.0) | 592 (63.3) |
Abbreviations: AREDS, Age-Related Eye Disease Study; DSGA, Directional Spread in Geographic Atrophy; FAM, Fundus Autofluorescence Imaging in Age-Related Macular Degeneration; GATE, Geographic Atrophy Treatment Evaluation.
a
The effect size (log odds) weighted age-related macular degeneration genetic risk score was calculated from 37 condition-associated, well-imputed variants normalized by the mean log odds of all 37 variants.8